Jessinntha James

Jessinntha James

Auto-generated profile, based on publicly available information

Jessinntha James

Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia (Health Campus), Kubang Kerian, Kelantan, Malaysia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Clinical and Translational Oncology
Verified
Journal Article
Open access
JJJessinntha James
Jessinntha James
AYAidy Irman Yajid
Aidy Irman Yajid
SYSahran Yahaya
Sahran Yahaya
SASARIMAH ABDULLAH
SARIMAH ABDULLAH
SSSharifah Emilia Tuan Sharif
Sharifah Emilia Tuan Sharif
MDM2 and CDK4 amplifications are well-established diagnostic markers in liposarcoma, but the clinical relevance of their co-amplification remains underexplored. This study evaluates their amplification characteristics and combined prognostic impact to inform risk stratification and patient management. Fluorescence in situ hybridisation (FISH) was performed on formalin-fixed paraffin-embedded samples of liposarcoma or benign lipomatous tumours (≥ 10 cm) histologically diagnosed at Hospital Pakar Universiti Sains Malaysia. Recurrence-free (RFS) and metastasis-free survival (MFS) across amplifications were determined using Kaplan-Meier. Recurrence associations with clinicopathological variables were examined using Cox regression. Among 86 cases, 27% were liposarcoma and 73% were benign tumours by FISH. Co-amplification (13%) was observed in all dedifferentiated liposarcoma (DDLS) and half of atypical lipomatous tumour/well-differentiated liposarcoma (ALT/WDLS) cases. MDM2 amplification without CDK4 (6%) was seen in ALT. Myxoid liposarcoma, pleomorphic liposarcoma, and benign tumours showed no amplification (81%). DDLS had higher MDM2 and CDK4 amplification ratios (4.4 and 2.8, respectively) than ALT/WDLS (2.9 and 2.6, respectively), with MDM2 consistently exceeding CDK4. Co-amplification associated with the shortest median RFS (34 months; p = 0.002) and MFS (83 months; p = 0.003). Surgery with chemotherapy (p = 0.042; HR = 26.50) associated with recurrence, while MDM2/CDK4 amplification was not an independent prognostic factor. MDM2 amplification was more consistent and quantitatively higher than CDK4, supporting its central role in tumourigenesis. While MDM2/CDK4 co-amplification was associated with poorer outcomes, it lacked independent prognostic value, reflecting the potential influence of other clinical variables. Nevertheless, co-amplification may hold clinical relevance in identifying high-risk liposarcoma subgroups.